


A NEW RING CONTRACTION OF PTERIDINE 5-OXIDES TO PURINES AND A 7-DEAZAPURINE BY THE 1,3-DIPOLAR CYCLOADDITION REACTION

Misuzu Ichiba, Hashime Kanazawa, Zenzo Tamura, and Keitaro Senga^{*}
 Pharmaceutical Institute, School of Medicine, Keio University
 35, Shinanomachi, Shinjuku-ku, Tokyo 160, Japan

Abstract — The 1,3-dipolar cycloaddition reaction of pteridine 5-oxides with dimethyl acetylenedicarboxylate resulted in a new ring contraction of the pyrazine moiety to give purines and a 7-deazapurine.

We have previously reported that the 1,3-dipolar cycloaddition reaction of pyrimido[5,4-*e*]-*as*-triazine 4-oxides with acetylenic esters causes a ring transformation of the *as*-triazine moiety to give 9-deazapurines.¹ Subsequently, we have also reported that the reaction of a thiazolo[5,4-*d*]pyrimidine 3-oxide with dimethyl acetylenedicarboxylate (DMAD) results in the ring transformation of the thiazole moiety to yield a 9-deazapurine *via* a pyrimido[4,5-*b*][1,4]thiazine.² On the basis of these findings, we have now investigated the ability to undergo 1,3-dipolar cycloaddition reaction of pteridine 5-oxides, and have found that the pyrazine moiety undergoes a new ring contraction to furnish purines and a 7-deazapurine. Heating of the pteridine 5-oxide (Ia)³ (0.001 mol) with DMAD (0.003 mol) in toluene (10 ml) at 120°C for 60 h resulted in the formation of the purine (IIa⁴: mp >300°C; 15%) and the 7-deazapurine (III: mp 241°C; 10%) along with the deoxygenated pteridine (IVa⁵: mp 260°C; 37%). The reaction was equally applicable to



a: R=C₆H₅; b: R=4-Cl-C₆H₄; c: R=4-MeO-C₆H₄

other pteridine 5-oxides (Ib-c)⁶ to give (IIb-c),⁴ III, and (IVb-c)⁵ in similar ratio of yields. Generally, IIa-c were readily precipitated out from the reaction solution, while III and IVa-c were isolated by the fractional crystallization of the filtrate from EtOH.

The characterization of II and IV was based on the spectral comparison with those of authentic samples,^{4,5} while that of III was derived from the following data. ¹H NMR (DMSO-d₆)_δ: 3.18 (N-Me), 3.48 (N-Me), 3.78 (O-Me), 3.81 (O-Me), 13.07 (NH, D₂O exchangeable); IR (KBr) cm⁻¹: 1750, 1710, 1650sh, 1640 (CO), 3230 (NH); UV λ_{max} (EtOH) nm (log ε): 254 (3.42), 360 (3.63); MS m/z: 323 (M⁺), 264 (M⁺-59), 232 (M⁺-91). In particular, the mass spectrum unequivocally suggested that the methoxycarbonyl and methoxalyl groups are attached at the positions 5 and 6, respectively,⁷ since the isomeric 9-deazapurine exhibits similar fragment pattern.⁸ Although the definite mechanism for the ring contraction is not clear at present, it is apparent that the reaction would involve 1,3-dipolar cycloaddition process since the treatment of IVa-c with DMAD under the same conditions resulted in the quantitative recovery of the starting materials. To our knowledge, the chemical conversion of pteridines to purines has two precedents,⁹ however, the ring contraction of pteridines to 7-deazapurines has not hitherto been reported.


ACKNOWLEDGEMENT

The authors are grateful to Drs. K. Nagahara and Y. Kurasawa of Kitasato University for ¹H NMR spectra as well as elemental analyses. We also thank Dr. K. Saito and Mr. H. Yamanaka of this school for mass spectra. A part of this work was supported by a Grant-in-Aid from Tokyo Biochemical Research Foundation.

REFERENCES AND NOTES

1. K. Senga, M. Ichiba, and S. Nishigaki, J. Org. Chem., **44**, 3830 (1979).
2. K. Senga, M. Ichiba, H. Kanazawa, and S. Nishigaki, J. Chem. Soc., Chem. Commun., 1981, 278.
3. W. Pfleiderer and W. Hutzenlaub, Chem. Ber., **106**, 3149 (1973).
4. K. Senga, K. Shimizu, and S. Nishigaki, Chem. Pharm. Bull., **25**, 495 (1977).
5. K. Senga, Y. Kanamori, and S. Nishigaki, Heterocycles, **6**, 693 (1977).
6. These compounds were prepared according to the reported procedure³: Ib, mp 243-245°C; Ic, mp 263-265°C.

7. The principal fragment path of III is as follows:



8. 6-Methoxalyl-7-methoxycarbonyl-1,3-dimethylpyrrolo[3,2-d]pyrimidin-2,4(1H,3H)-dione¹: MS $\text{m/z } 323 \text{ (M}^{\text{+}}\text{)}$, $264 \text{ (M}^{\text{+}}\text{-59)}$, $232 \text{ (M}^{\text{+}}\text{-91)}$.

9. W. Hutzenlaub, H. Yamamoto, G.B. Barlin, and W. Pfleiderer, *Chem. Ber.*, **106**, 3203 (1973); A. Nagel and H.C. van der Plas, *Chem. Pharm. Bull.*, **23**, 2678 (1975).

Received, 13th May, 1985